Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]FFMZ (2'-[18F]fluoroflumazenil) is a positron emission tomography (PET) radiopharmaceutical developed by RadioMedic. It is a derivative of flumazenil, a benzodiazepine receptor antagonist, radiolabeled with fluorine-18. The tracer binds with high affinity to the benzodiazepine site of the GABA(A) receptor complex. It is designed for the non-invasive imaging of GABAergic system changes associated with various pathologies. Primary research areas include neurodegenerative conditions like Alzheimer's disease and epilepsy, where GABA receptor density may be altered. It is also being investigated for peripheral applications such as pulmonary ischemia and as a tool for monitoring chemotherapy efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-[18F]fluoroflumazenil.